Jie Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jie Li has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Ariane Pessentheiner
Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California, USA
1 shared publication- Chen Wang
Department of Cardiovascular Medicine, First Affiliated Hospital of Xi’an Jiaotong University, China
1 shared publication - Jianjie Dong
Department of Cardiology, First Affiliated Hospital, and
1 shared publication - Jin Zhang
Cardiovascular Research Center, School of Basic Medical Sciences, First Affiliated Hospital, Xi’an Jiaotong University, Xi’an, China
1 shared publication - John Y. J. Shyy
Division of Cardiology, Department of Medicine, University of California, San Diego, La Jolla, CA
1 shared publication - Junhui Liu
Department of Cardiology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
1 shared publication
Latest Publications
- Open Access
- 3 December 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (23)
microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects cholesterol homeostasis by targeting hepatic LDL receptor (LDLR) for lysosomal degradation. Clinically, PCSK9 inhibitors effectively reduce LDL-cholesterol (LDL-C) levels and the incidence of cardiovascular events. Because microRNAs (miRs) are integral regulators of cholesterol homeostasis, we investigated the involvement of miR-483 in regulating LDL-C metabolism. Using in silico analysis, we predicted that miR-483-5p targets the 3′-UTR of PCSK9 mRNA. In HepG2 cells, miR-483-5p targeted the PCSK9 3′-UTR, leading to decreased PCSK9 protein and mRNA expression, increased LDLR expression, and enhanced LDL-C uptake. In hyperlipidemic mice and humans, serum levels of total cholesterol and LDL-C were inversely correlated with miR-483-5p levels. In mice, hepatic miR-483 overexpression increased LDLR levels by targeting Pcsk9 , with a significant reduction in plasma total cholesterol and LDL-C levels. Mechanistically, the cholesterol-lowering effect of miR-483-5p was significant in mice receiving AAV8 PCSK9-3′-UTR but not Ldlr -knockout mice or mice receiving AAV8 PCSK9-3′-UTR (ΔBS) with the miR-483-5p targeting site deleted. Thus, exogenously administered miR-483 or similarly optimized compounds have potential to ameliorate hypercholesterolemia.
- 3 December 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (23)
Open AccessmicroRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects cholesterol homeostasis by targeting hepatic LDL receptor (LDLR) for lysosomal degradation. Clinically, PCSK9 inhibitors effectively reduce LDL-cholesterol (LDL-C) levels and the incidence of cardiovascular events. Because microRNAs (miRs) are integral regulators of cholesterol homeostasis, we investigated the involvement of miR-483 in regulating LDL-C metabolism. Using in silico analysis, we predicted that miR-483-5p targets the 3′-UTR of PCSK9 mRNA. In HepG2 cells, miR-483-5p targeted the PCSK9 3′-UTR, leading to decreased PCSK9 protein and mRNA expression, increased LDLR expression, and enhanced LDL-C uptake. In hyperlipidemic mice and humans, serum levels of total cholesterol and LDL-C were inversely correlated with miR-483-5p levels. In mice, hepatic miR-483 overexpression increased LDLR levels by targeting Pcsk9 , with a significant reduction in plasma total cholesterol and LDL-C levels. Mechanistically, the cholesterol-lowering effect of miR-483-5p was significant in mice receiving AAV8 PCSK9-3′-UTR but not Ldlr -knockout mice or mice receiving AAV8 PCSK9-3′-UTR (ΔBS) with the miR-483-5p targeting site deleted. Thus, exogenously administered miR-483 or similarly optimized compounds have potential to ameliorate hypercholesterolemia.